biostudies-literatureUnknown9(4)Bornhauser M<h4>Importance</h4>The ideal postremission strategy in intermediate-risk acute myeloid leukemia (AML) in first complete remission (CR) has been a matter of debate.<h4>Objective</h4>To explore the optimal therapy for patients with intermediate-risk AML after first complete remission.<h4>Design, settings, and participants</h4>This investigator-initiated, open-label, 2-armed, phase 3 randomized clinical trial assessed patients at 16 hospitals in Germany from February 2, 2011, until July 1, 2018. Key eligibility criteria included cytogenetically defined intermediate-risk AML according to Medical Research Council classification, first CR or CR with incomplete blood cell count recovery after conventional induction therapy, age of 18 to 60 years, and availability of a human leukocyte antigen (HLAJAMA oncology519-526https://www.ebi.ac.uk/biostudies/studies/S-EPMC9912165biostudies-literatureAllogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.PMC9912165Schmid CThiede CBurchert ARosler WBeelen DGlass BHanel MEhninger GBerdel WEStolzel FSchafer-Eckart KStelljes MMuller LPSpiekermann KPlatzbecker UKlein SBug GSchetelig JServe HAlakel NBornhauser MTischer JJost EPfirrmann MMiddeke JMKramer MRollig CSchliemann CLenz GfalseAllogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.<h4>Importance</h4>The ideal postremission strategy in intermediate-risk acute myeloid leukemia (AML) in first complete remission (CR) has been a matter of debate.<h4>Objective</h4>To explore the optimal therapy for patients with intermediate-risk AML after first complete remission.<h4>Design, settings, and participants</h4>This investigator-initiated, open-label, 2-armed, phase 3 randomized clinical trial assessed patients at 16 hospitals in Germany from February 2, 2011, until July 1, 2018. Key eligibility criteria included cytogenetically defined intermediate-risk AML according to Medical Research Council classification, first CR or CR with incomplete blood cell count recovery after conventional induction therapy, age of 18 to 60 years, and availability of a human leukocyte antigen (HLA2023-01-01T00:00:00Z2023 Apr2026-05-28T21:47:47.959Z2025-04-05T14:48:11.595ZS-EPMC99121653675770610.1001/jamaoncol.2022.7605